Clinical Textbook of Addictive Disorders 3rd ed - R. Frances, S. Miller, A. Mack (Guilford, 2005) WW

Index 667pharmacotherapy with duallydiagnosed patients, 286–287Blackouts, 359Borderline personality disorders, 255alcohol abuse and, 82biosocial model, 618–620cocaine use and, 195–196comorbid substance use disorders, 253,254, 616dialectical behavioral therapy, 496–497, 615–616. See also Dialecticalbehavior therapyBuprenorphine, 380, 588for cocaine addiction, 202for opioid detoxification, 598opioid maintenance therapy with,601–602, 650therapeutic action, 13, 589Bupropion, 289adolescent treatment, 575, 576cocaine addiction treatment, 202for smoking cessation, 590Buspirone, 231for anxiety treatment in addictedpersons, 288–289clinical features, 238Butabarbital, 224CCAGE interview, 77, 278, 399Canceralcohol use and, 96–97tobacco use and, 106–107Cannabinoids, 6, 7Carbamazepinealcohol withdrawal management, 592cocaine addiction treatment, 202side effects, 592Carbohydrate-deficient transferin, 65,78, 98Cardiovascular systemalcohol effects, 92–93cocaine effects, 189, 190, 196–197methamphetamine effects, 207tobacco effects, 107, 112–113Case management, 494, 549in dialectical behavior therapy, 634Ceremony and ritual, 16, 18, 20, 21–22alcohol use in, 82–83tobacco use in, 105Chain analysis, 628–629Changed set point model of addiction,9–11Child abuse/neglect, 357Child Behavior Checklist, 54Chlordiazepoxide, 225, 591Chromatography techniques, 64Circuit parties, 261–262Cirrhosisalcoholic, 91, 92chronic hepatic encephalopathy, 41ethnic differences, 83Clomipramine, 309Clonazepam, 225, 229, 237–238, 315,591Clonidinefor opioid withdrawal, 597, 598for smoking cessation, 591therapeutic action, 13Clorazepate, 228, 229Clozapine, 287Club drugs, 260–262, 419Cocaine use and abuseaddiction risk, 192, 208–209addiction treatment, 202–206, 209,263, 651–654adulterants, 188, 197assessment, 200–201associated personality traits in, 256–257chronic use, 190–191, 197comorbid alcohol abuse, 79, 188–189,193crack cocaine, 184, 185, 186, 188,197–198, 415, 560elimination half-life, 191fetal exposure, 199–200, 209freebase, 187–188genetic factors in, 192–193health effects, 189, 190–191, 196–198HIV infection risk and, 415, 416,418–419